Skip to Content
Merck

B75956

4-Bromophenylboronic acid

≥95.0%

Synonym(s):

(p-Bromophenyl)boronic acid, 4-Bromobenzeneboronic acid, 4-Bromophenylboric acid, p-Bromobenzeneboronic acid, p-Bromophenylboric acid, NSC 25407

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
BrC6H4B(OH)2
CAS Number:
5467-74-3
Molecular Weight:
200.83
UNSPSC Code:
12352103
NACRES:
NA.22
PubChem Substance ID:
24892010
EC Number:
226-779-9
Beilstein/REAXYS Number:
2936347
MDL number:
MFCD00002104

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

QBLFZIBJXUQVRF-UHFFFAOYSA-N

InChI

1S/C6H6BBrO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4,9-10H

SMILES string

OB(O)c1ccc(Br)cc1

assay

≥95.0%, 95%

form

crystals

mp

284-288 °C (lit.)

Quality Level

200

Related Categories

Application

Reagent used for
  • Palladium catalyzed Suzuki-Miyaura cross-couplings
  • Pd(II)-catalyzed diastereoselective conjugate additions
  • Palladium-catalyzed stereoselective Heck-type reaction of allylic esters with arylboronic acids
  • Tandem-type Pd(II)-catalyzed oxidative Heck reaction and intramolecular C-H amidation sequence
  • Copper-mediated ligandless aerobic fluoroalkylation of arylboronic acids with fluoroalkyl iodides
  • Pd-catalyzed arylative cyclization of alkyne-tethered enals or enones via carbopalladation of alkynes
  • Copper-catalyzed cross-couplings

Reagent used in Preparation of
  • Gallate-based obovatol analogs with potential anti-tumor activity
  • Protein modulators and enzymatic and kinase inhibitors

Other Notes

Contains varying amounts of anhydride

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

Class I Designated Chemical Substances

prtr

B75956-5G: + B75956-VAR: + B75956-1G: + B75956-BULK:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

James A Jordan-Hore et al.
Organic letters, 14(10), 2508-2511 (2012-05-02)
Ligand-free cationic Pd(II) catalyst with NaNO3 as an additive is a highly active catalytic system for conjugate additions to sterically hindered γ-substituted cyclohexenones. More challenging γγ- and βγ-substrates also react well to produce products with quaternary centers in good dr.
Synthesis of obovatol derivatives and their preliminary evaluation as antitumor agents
Lee, M.-S.; et al.
Bull. Korean Chem. Soc., 28, 1601-1604 (2007)
Tahlia R Meola et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 129, 145-153 (2018-06-02)
The synergistic effect of nanosizing and lipid-based drug delivery systems (LBDDS) was explored to enhance formulation drug loading levels and improve drug solubilisation in the gastrointestinal environment. A novel formulation combining drug nanocrystals and silica-lipid hybrid (SLH) microparticles as a
Chuan Xiao et al.
Bioorganic & medicinal chemistry, 19(23), 7100-7110 (2011-11-01)
A series of purine nucleoside analogues bearing an aryl and hetaryl group in position 6 were prepared and their biological activities were assessed by in vitro CDK1/Cyclin B1 and CDK2/Cyclin A2 kinase assay. From the synthesized chemicals, three Xylocydine derivatives
Erin Tay et al.
Pharmaceutics, 12(1) (2019-12-28)
Lipid based formulations (LBFs) are commonly employed to enhance the absorption of highly lipophilic, poorly water-soluble drugs. However, the utility of LBFs can be limited by low drug solubility in the formulation. Isolation of ionizable drugs as low melting, lipophilic
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service